Introduction
While antipsychotic medications were initially approved based on clinical trials in adult populations, they are commonly prescribed "off-label" in pediatric and geriatric populations [1] [2] . In addition, they are increasingly being prescribed to children. Between the 1993 -1998 and 2005 -2009 time periods, visits including a prescription for antipsychotics per 100 people increased from 0.24 to 1.83 for children, 0.78 to 3.76 for adolescents, and 3.25 to 6.18 for adults; moreover, antipsychotics were included in 31.1% of youth visits to psychiatrists [3] . While antipsychotics are among the most effective drugs for the treatment of schizophrenia, mania, or acute psychotic reactions, these medications are often prescribed to children and adolescents for non-FDA approved indications, such as disruptive behaviors and aggression [4] [5] . Similarly, antipsychotics are frequently used in the elderly and are prescribed to more than a quarter of Medicare patients in nursing homes, with common conditions including dementia, delirium, and behavioral disturbances [2] . However, the use of these medications may result in unanticipated adverse events that are specific to the pediatric and geriatric populations [6] . In our study, we sought to elucidate the differences in adverse events between pediatric, adult, and geriatric populations using the FDA's Adverse Events Reporting System (AERS), a database that has collected information about adverse events since 1998 [7] . AERS is the FDA's primary tool for post-marketing adverse event surveillance, with over 250,000 adverse event reports annually [8] . A key strength of the AERS database is the ability to analyze a massive dataset and discover potentially new information regarding drug-related adverse events warranting further investigation. For instance, a recent paper probed the AERS database and found a potential link between amisulpride, cyamemazine, and olanzapine and torsadogenic risk [9] . Drug manufacturers are required to submit adverse event reports, while healthcare providers can voluntarily submit information.
Materials And Methods
We initially imported AERS quarterly data from January 2004 to September 2008 into the MySQL program (v.1.2.17) (Oracle Corp., Redwood Shores, CA). A table was created that mapped all the various drug names for antipsychotics to a generic name and a drug class (typical vs. atypical) using RxNorm (U.S. National Library of Medicine, Bethesda, MD) and Micromedex® (Truven Health Analytics, Greenwood Village, CO) ( Table 1) . Next, we joined this table with the AERS drug table (matching by DRUGNAME), the AERS demo table (matching by ISR, which stands for individual safety report), and the AERS REAC table (also matching by ISR). We first retrieved the total number of adverse events associated with each drug name, generic name, and drug class. Next, we created a yearage variable (which standardized all ages in AERS to be reported in years using the AGE and AGE_COD variables) as well as the GNDR_COD variable (which was reported as either "M" or "F") in order to repeat this analysis on the following five subgroups: yearage < 18 (pediatrics), 18 ≥ yearage ≤ 65 (adults), and yearage > 65 (geriatrics), GNDR_COD = "M" (males), and GNDR_COD = "F" (females).
Drug Name
Generic Name Drug Class 
Results
A summary of the populations we studied is shown in Table 2 .
Category Value
Total number of patients 61,380
Mean age ± SD 45.7 ± 20.0
Patients where age < 18 3,578
Patients where age ≥ 18 and age ≤ 65
32,660
Patients where age > 65
7,260
Patients where age is not available
17,882
Male patients 27,783
Female patients

29,780
Gender NA (null, unknown, or not specified) 3,817 
Typical Antipsychotics
Results were statistically significant either for pediatrics vs. adults, geriatrics vs. adults, or both. The significance threshold was 0.05/26 = 1.92 x 10 -3 . The p-values that R found to be extremely low are labeled as "0." Items that were statistically significant are in bold.
Eight antipsychotics were associated with a significant difference in the number of adverse events in the pediatric vs. adult populations, including aripiprazole, clozapine, fluphenazine, haloperidol, olanzapine, quetiapine, risperidone, and thiothixene. Ten antipsychotics were associated with a significant difference in the number of adverse events in the adult vs. geriatric populations, including aripiprazole, chlorpromazine, clozapine, fluphenazine, haloperidol, paliperidone, promazine, risperidone, thiothixene, and ziprasidone. When we compared the distributions of adverse events in the adult population to the pediatric and geriatric populations, Chi-square tests revealed that they were significantly different, as the p- Chi-square analysis was performed to compare the actual distribution of adverse events between the different populations for each drug. Seven commonly prescribed antipsychotics are presented in Table 7 : aripiprazole, clozapine, haloperidol, olanzapine, quetiapine, risperidone, and ziprasidone. The distribution of antipsychotic-related adverse events was compared between the pediatric, adult, and geriatric populations for seven major antipsychotics. For each major antipsychotic drug, adverse events were ordered by their frequency in the adult population, the top five were selected (and the rest designated as "other"), and their distribution was compared using the Chisquare test. The resultant p-value is in the final column.
The top five adverse events for less common drugs are listed in Table 8 . 
Generic
TABLE 8: Number and Type of Events in Each Population for Minor Drugs
The top five adverse events for the seven major antipsychotics mapped to MedDRA high-level terms are listed in Table 9 . 
Generic
Discussion
Overall, it was evident that both the frequencies and types of adverse events found in the adult population do not fit the distribution found in the pediatric or geriatric populations. As has been seen in prior studies, diabetes mellitus was frequently the most commonly reported adverse event in adults [10] , but this was not the case for either the pediatric or geriatric populations. One possible explanation for this is that since adults are more likely than children to have impaired fasting glucose in the first place (often due to a longer exposure to certain physiolologic factors, such as obesity and a sedentary lifestyle), they may be more predisposed to developing this complication. On the other hand, "weight increase" was frequently a topfive adverse effect for the major antipsychotic medications in children, consistent with prior meta-analyses [11] . Children were also more likely to exhibit side effects, such as "aggression," "abnormal behavior," and "suicidality," cognitive effects that may be seen more often in the developing brain. In particular, suicide attempts have previously been linked to antipsychotics in children with the AERS database [12] . For the geriatric population, neurological side effects, such as "confusional state" and "somnolence," figured more prominently. This suggests that the elderly, who are predisposed to neurological problems, may be more severely affected by the neurological sequelae of antipsychotics. In fact, the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) trial, studying elderly patients with Alzheimer's disease, showed that atypical antipsychotics were associated with worsening cognitive function comparable to an additional year's worth of cognitive decline compared to placebo [13] .
Although we also analyzed differences in high-level terms between pediatric, adult, and geriatric populations, we realized that going to the next higher level grouping for MedDRA terms was not particularly illustrative. For instance, how does one distinguish "Neurological signs and symptoms" from "Disturbances in consciousness," and what exactly constitutes "General signs and symptoms?" These were among the most commonly reported high-level terms.
Our analysis of the literature revealed that there were adverse events that frequently had reports in AERS; yet, these events were not commonly mentioned in the literature. In the adult population, amongst the top five adverse events for the seven major antipsychotics, only pancreatitis in patients taking quetiapine had fewer than five reports in the literature. The analyses for the pediatric and geriatric populations generated comparatively more adverse events that were not commonly found in the literature. The result for quetiapine in the geriatric population is interesting, given reports of its association with pneumonia [14] .
The limitations of the FDA AERS database include the lack of information on the number of individuals taking the various antipsychotic medications in each age group, which could have served as a "denominator" in our study. Due to this lack of a denominator, when comparing the total number of adverse events across the pediatric, adult, and geriatric populations, it was difficult to determine whether variations in the relative distribution of adverse events between the three age groups was truly due to differences in the rate of adverse events rather than simply variations in prescription frequency. For instance, this could be related to prescription trends or when the medications were released. Fortunately, the issue of a denominator was not problematic when comparing the particular side effect profile between the three populations for any given drug. Another issue is the fact that the correlation of a particular medication with an adverse event does not necessarily prove causation. For instance, an individual who is prone to a particular adverse event may be more likely to take an antipsychotic. Another potential problem is recall bias, as a physician who knows a patient is taking a given drug may be more likely to report adverse events that are widely known to be associated with that drug. Nevertheless, the sheer volume of the AERS database and its vast scope make it a useful tool for studying drug-related adverse events.
Conclusions
Overall, we were able to show that there are significant differences in both the numbers and types of adverse events between the pediatric, adult, and geriatric populations. In addition, this study offers a number of drug and adverse event combinations for follow-up analysis. Given the fact that these medications were overwhelmingly tested on the adult population and are commonly prescribed off-label, it is imperative that clinicians remain mindful of these differences when prescribing these medications in populations for whom the drugs were never formally tested.
